An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 206843
Company: BRISTOL-MYERS SQUIBB

Summary Review

Products on NDA 206843

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
DAKLINZA	DACLATASVIR DIHYDROCHLORIDE	EQ 30MG BASE	TABLET;ORAL	Discontinued	None	Yes	No
DAKLINZA	DACLATASVIR DIHYDROCHLORIDE	EQ 60MG BASE	TABLET;ORAL	Discontinued	None	Yes	No
DAKLINZA	DACLATASVIR DIHYDROCHLORIDE	EQ 90MG BASE	TABLET;ORAL	Discontinued	None	Yes	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 206843

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
07/24/2015	ORIG-1	Approval	Type 1 - New Molecular Entity	PRIORITY	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206843s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206843Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206843Orig1s000TOC.html

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/16/2019	SUPPL-8	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206843s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/206843Orig1s008ltr.pdf
11/09/2017	SUPPL-7	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206843s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206843Orig1s007ltr.pdf
02/14/2017	SUPPL-6	Labeling-Package Insert, Labeling-Patient Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206843s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206843Orig1s006ltr.pdf
12/21/2016	SUPPL-5	Manufacturing (CMC)		Label is not available on this site.
04/13/2016	SUPPL-4	Manufacturing (CMC)	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206843s004lbl.pdf
02/05/2016	SUPPL-3	Efficacy-New Indication	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206843s001s002s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/206843Orig1s003ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206843Orig1s001,s003TOC.html https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2016/206843Orig1s001, s003SumR.pdf
02/05/2016	SUPPL-2	Efficacy-New Indication	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206843s001s002s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/206843Orig1s002ltr.pdf
02/05/2016	SUPPL-1	Efficacy-New Indication	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206843s001s002s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/206843Orig1s001ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206843Orig1s001,s003TOC.html https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2016/206843Orig1s001, s003SumR.pdf

Labels for NDA 206843

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/16/2019	SUPPL-8	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206843s008lbl.pdf
11/09/2017	SUPPL-7	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206843s007lbl.pdf
02/14/2017	SUPPL-6	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206843s006lbl.pdf
02/14/2017	SUPPL-6	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206843s006lbl.pdf
04/13/2016	SUPPL-4	Manufacturing (CMC)	Label (PDF)	This supplement type does not usually require new labeling.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206843s004lbl.pdf
02/05/2016	SUPPL-3	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206843s001s002s003lbl.pdf
02/05/2016	SUPPL-2	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206843s001s002s003lbl.pdf
02/05/2016	SUPPL-1	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206843s001s002s003lbl.pdf
07/24/2015	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206843s000lbl.pdf

Top